Cadila Pharma launches world's first novel 3-dose vaccine against rabies
The three-dose vaccine, named as 'ThRabis', is a recombinant nano-particle based G protein vaccine which is prepared using Virus-like Particle technology09-04-2022
09-04-2022
Zydus Lifesciences Ltd - 532321 - Certificate Under Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Year Ended On March 31, 2022
Certificate under Regulation 7(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended on March 31, 202206-04-2022
Zydus Lifesciences Ltd - 532321 - Statement Of Investor Complaints For The Quarter Ended March 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0440 Name of the Signatory :- Dhaval N SoniDesignation :- Company Secretary and Compliance Officer05-04-2022
Zydus Lifesciences Ltd - 532321 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended on March 31, 202205-04-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
The Lancet publishes Phase III data of ZyCoV-D01-04-2022
Zydus Lifesciences Ltd - 532321 - Closure of Trading Window
We hereby inform that the trading window shall remain closed from April 1, 2022 till 48 hours after the declaration of audited financial results for the quarter / year ending on March 31, 2022 for the Directors and Designated Persons and their immediate relatives, for trading in the equity shares of the Company.25-03-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Fortress Biotech and Cyprium Therapeutics alongwith Zydus' Sentynl Therapeutics Announce CUTX-101, Copper Histidinate Data to be Presented at 2022 American College of Medical Genetics Annual Clinical Genetics Meeting21-03-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives Prior Approval Supplement (PAS) approval from USFDA for Mycophenolate Mofetil for Injection USP21-03-2022
Cadila, Torrent get licence to make generic version of Pfizer's Covid pill
Pharma firms enter into licensing agreement with Medicine Patent Pool to use nirmatrelvir compound for making PAXLOVID17-03-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Acquisition
Acquisition of stake up to 11.86% of the paid-up equity share capital of AMP Energy Green Nine Private Limited.16-03-2022